Benzinga | Jan 11, 2022 06:58AM EST

Wells Fargo Maintains Overweight on Celyad Oncology, Lowers Price Target to $11

Wells Fargo analyst John Abbott maintains Celyad Oncology (NASDAQ:CYAD) with a Overweight and lowers the price target from $20 to $11.